Clinical Trial Update: Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD [Phase 3]

View source ↗

Summary

Phase 3 trial comparing PT009 with PT005, PT008, and Symbicort in moderate to very severe COPD completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PT005
• PT008
• PT009
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: Chronic Obstructive Pulmonary Disorder | Phase 3 | Status: COMPLETED | Results posted: 2019-09-24